CSPC Pharmaceutical Group Limited

As of June 30, 2026, CSPC Pharmaceuticals Group Ltd. carries a market capitalization of 11.12B, placing it among publicly traded companies globally. Its enterprise value stands at 8.75B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

CSPC Pharmaceuticals Group Ltd.'s next confirmed earnings release is scheduled for March 24, 2027.

As of June 30, 2026, CSPC Pharmaceuticals Group Ltd. has 11.41B shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, CSPC Pharmaceuticals Group Ltd. maintains a current ratio of 2.14, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 6, 2026, CSPC Pharmaceuticals Group Ltd.'s stock has declined approximately 13.28% over the past 52 weeks. The 50-day moving average sits at 0.92, while the 200-day moving average is 1.00.

As of June 30, 2026, CSPC Pharmaceuticals Group Ltd. holds 2.73B in cash and equivalents against 96.17M in total debt, resulting in a net debt position of -1.41B. Total book value stands at 5.55B, with working capital of 2.42B providing operational flexibility.

CSPC Pharmaceuticals Group Ltd.'s most recent stock split took place on October 15, 2020 with a 5:8 split ratio.